TY - JOUR
T1 - Health care utilization and behavior changes after workplace genetic testing at a large US health care system
AU - INSIGHT @ Work Consortium
AU - Charnysh, Elizabeth
AU - Pal, Subhamoy
AU - Reader, Jonathan M.
AU - Uhlmann, Wendy R.
AU - McCain, Sarah
AU - Sanghavi, Kunal
AU - Blasco, Drew
AU - Brandt, Rachael
AU - Feero, William Gregory
AU - Ferber, Rebecca
AU - Giri, Veda N.
AU - Hendy, Katherine
AU - Prince, Anya E.R.
AU - Lee, Charles
AU - Roberts, J. Scott
AU - Crumpler, Nicole
AU - Leader, Amy
AU - Mathews, Debra
AU - Ryan, Kerry
AU - Spector-Bagdady, Kayte
AU - Vogle, Alyx
AU - Brothers, Kyle
AU - Clayton, Ellen Wright
AU - Deverka, Patricia
AU - Ellis, Thomas
AU - Goldenberg, Aaron
AU - Mockus, Susan
AU - Morton, Cynthia Casson
AU - Rueter, Jens
AU - Witham, Brett
AU - Bessey, Ethan
AU - Gordon, Erynn
AU - Lee, La Tasha
AU - Roberts, Jessica
AU - Saidi, Fatima
N1 - Publisher Copyright:
© 2024 The Authors
PY - 2024/8
Y1 - 2024/8
N2 - Purpose: This study explored employee health behavior changes and health care utilization after workplace genetic testing (wGT). Wellness-program-associated wGT seeks to improve employee health, but the related health implications are unknown. Methods: Employees of a large US health care system offering wGT (cancer, heart disease, and pharmacogenomics [PGx]) were sent electronic surveys. Self-reported data from those who received test results were analyzed. Descriptive statistics characterized responses, whereas logistic regression analyses explored correlates of responses to wGT. Results: 53.9% (n = 418/776) of respondents (88.3% female, mean age = 44 years) reported receiving wGT results. 12.0% (n = 48/399) received results indicating increased risk (IR) of cancer, 9.5% (n = 38/398) had IR of heart disease, and 31.4% (n = 125/398) received informative PGx results. IR results for cancer and/or heart disease (n = 67) were associated with health behavior changes (adjusted odds ratio: 3.23; 95% CI 1.75, 6.13; P <.001) and health care utilization (adjusted odds ratio: 8.60; 95% CI 4.43, 17.5; P <.001). Informative PGx results (n = 125) were associated with medication changes (PGx-informative: 15.2%; PGx-uninformative: 4.8%; P =.002). Conclusion: This study explored employee responses to wGT, contributing to the understanding of the ethical and social implications of wGT. Receiving IR results from wGT may promote health behavior changes and health care utilization in employees.
AB - Purpose: This study explored employee health behavior changes and health care utilization after workplace genetic testing (wGT). Wellness-program-associated wGT seeks to improve employee health, but the related health implications are unknown. Methods: Employees of a large US health care system offering wGT (cancer, heart disease, and pharmacogenomics [PGx]) were sent electronic surveys. Self-reported data from those who received test results were analyzed. Descriptive statistics characterized responses, whereas logistic regression analyses explored correlates of responses to wGT. Results: 53.9% (n = 418/776) of respondents (88.3% female, mean age = 44 years) reported receiving wGT results. 12.0% (n = 48/399) received results indicating increased risk (IR) of cancer, 9.5% (n = 38/398) had IR of heart disease, and 31.4% (n = 125/398) received informative PGx results. IR results for cancer and/or heart disease (n = 67) were associated with health behavior changes (adjusted odds ratio: 3.23; 95% CI 1.75, 6.13; P <.001) and health care utilization (adjusted odds ratio: 8.60; 95% CI 4.43, 17.5; P <.001). Informative PGx results (n = 125) were associated with medication changes (PGx-informative: 15.2%; PGx-uninformative: 4.8%; P =.002). Conclusion: This study explored employee responses to wGT, contributing to the understanding of the ethical and social implications of wGT. Receiving IR results from wGT may promote health behavior changes and health care utilization in employees.
KW - Behavior changes
KW - ELSI
KW - Employees
KW - Wellness programs
KW - Workplace genetic testing
UR - http://www.scopus.com/inward/record.url?scp=85196045680&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85196045680&partnerID=8YFLogxK
U2 - 10.1016/j.gim.2024.101160
DO - 10.1016/j.gim.2024.101160
M3 - Article
C2 - 38733246
AN - SCOPUS:85196045680
SN - 1098-3600
VL - 26
JO - Genetics in Medicine
JF - Genetics in Medicine
IS - 8
M1 - 101160
ER -